Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
/ 493 items
#XY Event-Driven Stocks↓
Veradermics Surges on Analyst Backing and Promising Oral Hair Loss Data in Women
90% of women reported improved hair coverage with no major safety issues.
Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Spero Sells Portion of Utebzi Economics for $105M to Fuel SP001 Development
Spero Therapeutics monetizes its Utebzi royalty stream in a $105M non-dilutive financing deal with Healthcare Royalty, extending cash runway to 2H 2029 while funding SP001 development.
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
HCA Healthcare Cuts 2026 Earnings Guidance as Uninsured Patient Surge Weighs on Profits
$400M pre-tax hit in Q2 as ACA subsidies expire.